Pharmaceuticals News and Research

RSS

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

24 Mar 2014

State highlights: Ark. court reverses $1.2B Medicaid drug judgment; Fla. officials overhauling child welfare agency

The Arkansas Supreme Court reversed a $1.2 billion judgment against Johnson & Johnson on Thursday, finding that the state attorney general erred by suing under a law that applied to health care facilities, not drug companies. The judgment, one of the largest in history for a state fraud case, was imposed in 2012 after a jury concluded that Johnson & Johnson had improperly marketed and concealed the risks of Risperdal, an antipsychotic drug (Thomas, 3/2).

24 Mar 2014

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

24 Mar 2014

First Edition: March 21, 2014

Today's early morning highlights from the major news organizations, including a new examination of Ezekiel Emanuel's book about the crafting of the health law and President Obama's latest push to boost enrollment.

21 Mar 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

21 Mar 2014

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today provided a clinical update on its lead antibiotic candidate, eravacycline, and its Phase 3 global clinical program IGNITE (Investigating Gram-negative Infections Treated with Eravacycline).

21 Mar 2014

NIH awards $28M grant to establish new center for excellence to find treatment for Ebola virus

The National Institutes of Health has awarded a five-year, $28 million grant to establish a new center for excellence to find an antibody "cocktail" to fight two types of viruses that cause severe hemorrhagic fever, including the deadly Ebola virus. The project involves researchers from 15 institutions, including Kartik Chandran, Ph.D., and Jonathan Lai, Ph.D., at Albert Einstein College of Medicine of Yeshiva University. Einstein will receive approximately $4 million of the total grant.

21 Mar 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

MRI magnetic fields may diagnose, treat balance disorders and dizziness, say researchers

Expanding on earlier research, Johns Hopkins researchers report that people with balance disorders or dizziness traceable to an inner-ear disturbance show distinctive abnormal eye movements when the affected ear is exposed to the strong pull of an MRI’s magnetic field.

20 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Concordia Healthcare Corp., announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

20 Mar 2014

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.

20 Mar 2014

Daiichi Sankyo files NDA for development and marketing of Methylene Blue medicinal product in Japan

Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm’s Proveblue Methylene Blue active substance.

20 Mar 2014

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Université Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.

20 Mar 2014

Study: Infections caused by antibiotic-resistant bacteria are on rise in U.S. children

Infections caused by a concerning type of antibiotic-resistant bacteria are on the rise in U.S. children, according to a new study published in the Journal of the Pediatric Infectious Diseases Society and available online.

20 Mar 2014

Scientists step in with new way to determine drug safety without using animals

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety and drug interactions — without using animals.

19 Mar 2014

Horizon Pharma secures $250 million in acquisition financing from Deerfield Management

Deerfield Management Company announced today that it has provided up to $250 million in acquisition financing to Horizon Pharma, Inc. for the acquisition of Vidara Therapeutics International Ltd.

19 Mar 2014

Pharmaceuticals News and Research

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

FDA approves Xolair for treatment of chronic idiopathic urticaria

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

State highlights: Ark. court reverses $1.2B Medicaid drug judgment; Fla. officials overhauling child welfare agency

Researchers developing new medication to tackle river blindness and elephantiasis

First Edition: March 21, 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

NIH awards $28M grant to establish new center for excellence to find treatment for Ebola virus

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

MRI magnetic fields may diagnose, treat balance disorders and dizziness, say researchers

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Daiichi Sankyo files NDA for development and marketing of Methylene Blue medicinal product in Japan

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

Study: Infections caused by antibiotic-resistant bacteria are on rise in U.S. children

Scientists step in with new way to determine drug safety without using animals

Horizon Pharma secures $250 million in acquisition financing from Deerfield Management

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring